A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
Financial Summary
| Share Statistics | CZMWY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,320.3 | $422.9 | 60% |
|
| Shares Out (Mil) | 98.6 | 41.4 | 62% |
|
| Institutional Ownership | 50.0% | 83.6% | 30% |
|
| Float (Mil) | 34.7 | 34.9 | 39% |
|
| Beta | 1.35 | 0.88 | 78% |
|
| Avg Daily Volume (000s) | 3 | 409 | 11% |
|
| Price Change (52-week) |
(23.9%) | 66.3% | 26% |
|
| Growth | CZMWY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.8% | 11.9% | 61% |
|
| Net Income (5yr) | 2.9% | (5.9%) | 44% |
|
| EPS (5yr) | 3.3% | 10.4% | 36 |
|
| Dividends (5yr) | 1.9% | 0.0% | 72% |
|
| Cash Flow (5yr) | 19.6% | (16.2%) | 79% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CZMWY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,492 | $123 | 63% |
|
| Net Income (TTM) (Mil) | $139 | ($9) | 64% |
|
| EPS (TTM) | $1.593 | ($0.400) | 67% |
|
| Operating Cash Flow (TTM) (Mil) | na | ($3) | na |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $22 | 0% |
|
| Enterprise Value (Q1) (Mil) | $3,861 | $418 | 58% |
|
| Valuation | CZMWY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 3.13 | na |
|
| P/E | na | 28.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | CZMWY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 51.6% | 58.7% | 64% |
|
| Net Margin | 5.6% | (6.9%) | 50% |
|
| ROA | na | (12.3%) | na |
|
| ROE | 11.6% | (12.3%) | 62% |
|
| Liabilities to Assets | na | 46.0% | na |
|
| F-Score | na | 4 | na |
|
Carl Zeiss Meditec AG did not pass any screens on 8/21/2026.
